ClinicalTrials.gg
CompletedNCT03466229AndrofertiUpdated Mar 16, 2018

Impact of Antioxidant Treatment on DNA Fragmentation Index

An interventional study of Androferti and Placebo in Male Infertility, sponsored by Region Skane. Completed. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2018-03-16.

Sponsored by Region Skane · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Jul 2015, registered Mar 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Increased sperm DNA Fragmentation Index implies decreased male fertility in vivo and in vitro. There is need for developing new strategies for improvement of male fertility. The study aims to investigate whether high sperm DNA Integration Index can be treated by use of antioxidants.

Read the detailed description

In the Western world, approximately 15-20% of couples experience infertility problems during their reproductive life. In this context ´'infertility' is defined as 12 months of unprotected intercourse without getting pregnant.

Although there is limited access to reliable diagnostic methods, it is assumed that in at least 50% of all cases 'male subfertility' is a contributing or the main cause of the infertility of the couple. The gold standard in assessment of male reproductive function is standard semen analysis including evaluation of sperm number, motility and morphology. Although efforts have been made in to improve and standardise the methodology for semen analysis, there are no well established cut off levels for sperm concentration, motility or morphology which accurately predict the chance of pregnancy or indicate which assisted reproductive technique (ART) - the most frequent therapy for infertility- will ultimately be the most effective. This lack of diagnostic tools is not only hampering proper management of infertility but also represents a serious limitation in relation to the understanding of biological underpinnings of the disorder and as a consequence, the development of cause related treatment modalities.

Although various novel alternative methods of assessing semen quality have been developed, so far, none have contributed to or altered our clinical approach to the treatment of infertile couples. During the passed two decades a lot of attention has been paid to impairment of sperm DNA integrity as a possible cause of male subfertility. There are different techniques currently available for the assessment of sperm DNA integrity e.g. Sperm Chromatin Structure Assay (SCSA®), Comet, TUNEL and sperm chromatin dispersion test. Generally, the use of these tests has shown an increased proportion of sperm with fragmented DNA structure among subfertile men as compared to proven fertile or men from general population. Although measuring different characteristics of the status of sperm DNA (e.g. presence of single and double strand breaks, propensity to damage and probable cause of the fragmentation), comparisons of the results obtained with two or more of these tests show a correlation coefficient of a magnitude 0.4 to 0.6, indicating that, although not completely overlapping, the tests to a certain extent assess some of the same characteristics of sperm DNA. Another interesting finding is that there is only a weak to moderate correlation between standard sperm parameters and measures of DNA integrity, the level of association (correlation coefficient \~ 0.6) the most pronounced being for motility. This means that assessment of sperm chromatin integrity adds to the information obtained by standard semen analysis.

The most appraised, standardised and studied of the sperm nDNA tests is the SCSA® which is based on a very well defined protocol for handling of samples and subsequent data analysis. The robustness of the techniques was exemplified by a comparison of the SCSA® analysis of almost 200 samples results performed by two independent laboratories which found a correlation coefficient of 0.9 with mean difference between the DNA Fragmentation Index (DFI) results of about 1%. A further advantage of the SCSA® method over the remaining assessment techniques is the relatively large number of studies that have utilised the technique in clinical settings constituting a considerable record of the method's performance in predicting fertility outcome.

Briefly, these data indicate that the chance of spontaneous pregnancy decreases at DFI levels above 20% and approaches zero if DFI exceeds 30%. This is also true for Intrauterine insemination (IUI). However, it seems that even spermatozoa from samples with high DFI can be used for in vitro fertilisation by standard IVF or ICSI, with some data suggesting that ICSI might actually be more efficient using samples with high (>30%) DFI. A finding, which may at first appear paradoxical but may be a reflection of the relative probability of fortuitously selecting a sperm with intact DNA. The data regarding fertilisation rate, embryo quality and risk of miscarriage in relation to DFI are also conflicting.

The biological mechanisms responsible for DNA strand breaks and other types of impairment of sperm DNA integrity are not completely known. Amongst others incomplete DNA repair during spermiogenesis, abortive apoptosis and/or increased level of oxidative stress have been suggested as possible options .

The overall aim of this project is to evaluate effect of restoring oxidant balance using Androferti, (Q Pharma Laboratories; Alicante, Spain) on sperm DNA integrity in subfertile men with high level of DFI.

02

Conditions studied

  • Male Infertility

Browse trials for

Keywords

  • sperm DNA strand breaks
  • antioxidants
03

In context

Infertility, Male

282 studies on the registry are indexed under Infertility, Male; 65 are open to participants now.

This study's enrollment of 79 is close to the median of 80 across 187 interventional studies indexed under Infertility, Male.

Browse Infertility, Male studies →

Lead sponsor

Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Referred due to infertility
  2. Age: 18-50 years,
  3. Non-smoking,
  4. Sperm DNA Fragmentation Index >25%

Exclusion criteria

Exclusion Criteria:

  1. (BMI) ≥30,
  2. FSH outside the normal range of 2-8 IU/L,g)
  3. LH outside the normal range of 2-10 IU/L,
  4. T \< 10nmol/L
  5. Treated with antihypertensive drugs, hormones, statins, psychotropic drugs, or oral cortisone for the last six months,
  6. History of anabolic steroids use,
  7. Taking antioxidant supplementation the last six months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
79 participants (actual)

Study arms

  • Active comparator
    Antioxidant

    Androferti - 1 twice per day

    Dietary Supplement: Androferti

  • Placebo comparator
    Placebo

    Placebo - 1 twice per day

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementAndroferti
  • Dietary supplementPlacebo
06

What researchers measure

Primary outcomes

  1. DFI_3

    3_month_change_DNA Fragmentation Index assessed by Sperm Chromatin

    Time frame: Change in DNA Fragmentation Index from Baseline to 3 months

  2. DFI_6

    6_month_change_DNA Fragmentation Index assessed by Sperm Chromatin Structure Assay

    Time frame: Change in DNA Fragmentation Index from Baseline to 6 months

Secondary outcomes

  1. Concentration_3

    Change sperm concentration 3 months

    Time frame: Change in sperm concentration from baseline to 3 months in millions/mL

  2. Concentration_6

    Change sperm concentration 6 months

    Time frame: Change in sperm concentration from baseline to 6 months in millions/mL

  3. Motility_3

    Change sperm motility 3 months

    Time frame: Change in sperm motility from baseline to 3 months in %

  4. Motility_6

    Change sperm motility 6 months

    Time frame: Change in sperm motility from baseline to 6 months in %

  5. Morphology_3

    Change sperm morphology 3 months

    Time frame: Change in sperm morphology from baseline to 3 months in %

  6. Morphology_6

    Change sperm morphology 6 months

    Time frame: Change in sperm morphology from baseline to 6 months in %

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Stenqvist A, Oleszczuk K, Leijonhufvud I, Giwercman A. Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology. 2018 Nov;6(6):811-816. doi: 10.1111/andr.12547. Epub 2018 Oct 8. PubMed 30298673 ↗

Individual participant data

Plan to share: Undecided — Plan to share IPD has not yet been discussed

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Dec 2016, 17 months.

Of 77 non-industry interventional studies with no phase under Infertility, Male, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 17 months is below that.

Counting every sponsor, half of 92 studies reached it within 34 months; a quarter within 17 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2018
First posted
Mar 15, 2018
StartActual
Jul 1, 2015
Primary completionActual
Dec 31, 2016
CompletionActual
Dec 31, 2016
Last update
Mar 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03466229
Lead sponsor
Region Skane
Collaborators
Q-Pharma, Octean
Responsible party
Aleksander Giwercman (Professor, Region Skane) — Principal investigator
First posted
Mar 15, 2018
Start date
Jul 1, 2015
Primary completion
Dec 31, 2016
Completion
Dec 31, 2016
Last update
Mar 16, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion